ホーム › 大腸癌 › ペンシルベニア › Pittsburgh
Pittsburgh、PAにおける大腸癌の臨床試験
Pittsburghとその周辺地域（約30マイル以内）の拠点で、大腸癌に関する32件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Pittsburgh
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
被験者募集中第2相
- Allegheny General Hospital, Pittsburgh
- West Penn Hospital, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #32, Pittsburgh
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
被験者募集中第1相
- Research Site, Pittsburgh
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
被験者募集中第1/2相
- University of Pittsburgh Medical Center (UPMC), Pittsburgh
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
被験者募集中第3相
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center, Pittsburgh
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
被験者募集中第1相
- Research Site, Pittsburgh
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
被験者募集中第3相
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center, Pittsburgh
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
被験者募集中第3相
- Allegheny General Hospital, Pittsburgh
- West Penn Hospital, Pittsburgh
- Jefferson Hospital, Jefferson Hills · 11マイル先
- 他2件
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
被験者募集中第2/3相
- Local Institution - 0604, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Allegheny Health Network, Pittsburgh
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
被験者募集中第3相
- Allegheny General Hospital Cancer Institute, Pittsburgh
- Hillman Cancer Center, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
被験者募集中第3相
- Clinical Study Site, Pittsburgh
- Clinical Study Site, Pittsburgh
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
被験者募集中第2相
- UPMC / University of Pittsburgh Medical Center, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
被験者募集中第2相
- UPMC Hillman Cancer Center, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
被験者募集中第1/2相
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
被験者募集中第3相
- UPMC Hillman Cancer Center - St Margarets, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC Hillman Cancer Center - Passavant (HOA), Pittsburgh
- 他6件
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
被験者募集中第1相
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Pittsburgh
Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar
被験者募集中
- Allegheny Health Network, Pittsburgh
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
被験者募集中第1相
- University of Pittsburg Medical Center (UPCM), Pittsburgh
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
被験者募集中第1/2相
- UPMC Hillman Cancer Center, Pittsburgh
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
被験者募集中
- AHN West Penn Hospital, Pittsburgh
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
他の都市における大腸癌の試験
- Houston, TX102件の研究
- New York City, NY78件の研究
- Nashville, TN69件の研究
- Boston, MA63件の研究
- Los Angeles, CA59件の研究
- Arlington, VA52件の研究
- St. Louis, MO50件の研究
- San Antonio, TX46件の研究
- Philadelphia, PA44件の研究
- Grand Rapids, MI40件の研究
- Baldwin Park, CA37件の研究
- Chicago, IL34件の研究
Pittsburghにおける他の研究
- 非小細胞肺癌48件の研究
- がん（全種類）41件の研究
- 乳がん39件の研究
- 転移性癌31件の研究
- 悪性黒色腫31件の研究
- 卵巣がん30件の研究
- 子宮内膜がん23件の研究
- 前立腺がん23件の研究
- 肺がん23件の研究
- 頭頸部扁平上皮癌22件の研究
- 脳卒中22件の研究
- うつ病22件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。